Developing an Integrated Psychotherapy With Cognitive-behavioral Therapy and Biofeedback Therapy for Somatic Symptom Disorder

Sponsor
National Taiwan University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05792930
Collaborator
(none)
60
2
30

Study Details

Study Description

Brief Summary

This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy on treatment of somatic symptom disorder. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 and Health Anxiety Questionnaire are the primary endpoints.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: cognitive-behavioral therapy and biofeedback therapy
N/A

Detailed Description

Somatic symptom disorder (SSD) is a psychiatric disorder featured with somatic distress and related psychological phenomena. In the past several years, our research team has investigated several aspects of SSD, including psychopathology, epidemiology, mechanism, and diagnostic biomarkers. But the aspect about treatment on SSD has not been comprehensively explored.

In literature, the treatment of SSD can be separated into physical and psychological approaches. The physical approach includes pharmacotherapy and magnetic/electrical neuromodulation. Among several types of psychotherapies, cognitive behavioral therapy (CBT) has the most evidence. Previous studies have disclosed SSD patients to have following cognitive or behavioral features: selective attention on somatic distress; memory bias on the severe health conditions; all-or-none cognition about health; organic attribution style; catastrophizing cognitive pattern about health; high motivation of concerning issues about health; inadequate reassurance-seeking behavior; the assumption about the connection between rest and somatic distress, etc.

Biofeedback therapy works by measuring several biological signals related with stress and relaxation (such as heart rate, skin conductance, electromyography, electroencephalography, and finger temperature); feedback of these signals to the subjects can help them more clearly understand the association between their behavior/cognition and relaxation. Biofeedback therapy has been extensively applied in the psychosomatic field.

This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 (PHQ-15) and Health Anxiety Questionnaire (HAQ) are the primary endpoints; the changes of other psychological and biological measurements are viewed as secondary endpoints.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Developing an Integrated Psychotherapy With Cognitive-behavioral Therapy and Biofeedback Therapy for Somatic Symptom Disorder: a Randomized Controlled Trial
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Group

The experimental group will receive cognitive-behavioral therapy (CBT) and biofeedback therapy.

Behavioral: cognitive-behavioral therapy and biofeedback therapy
Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.

No Intervention: Control Group

The design of control group is waiting list control; their data will be collected without intervention during the observation period. After the observation period, psychotherapy (CBT and biofeedback, the same as intervention) will be arranged.

Outcome Measures

Primary Outcome Measures

  1. Scores of Patient Health Questionnaire-15 (PHQ-15) [Week 12 (comparing with the data in week 0)]

    Measurement of somatic distress. Score range is 0 to 30; higher score means more severe somatic distress

  2. Scores of Health Anxiety Questionnaire (HAQ) [Week 12 (comparing with the data in week 0)]

    Measurement of health anxiety. Score range is 0 to 63; higher score means more severe health anxiety

Secondary Outcome Measures

  1. Scores of Beck Depression Inventory-II (BDI-II) [Week 12 (comparing with the data in week 0)]

    Measurement of depression. Score range is 0 to 63; higher score means more severe depression

  2. Scores of Beck Anxiety Inventory (BAI) [Week 12 (comparing with the data in week 0)]

    Measurement of anxiety. Score range is 0 to 63; higher score means more severe anxiety

  3. Scores of Cognitions About Body and Health Questionnaire (CABAH) [Week 12 (comparing with the data in week 0)]

    Measurement of cognitions about health. Score range is 0 to 117; higher score means more severe cognitive distortion about health

  4. Heart rate variability [Week 12 (comparing with the data in week 0)]

    Measurement of parasympathetic activity

  5. Skin conductance [Week 12 (comparing with the data in week 0)]

    Measurement of sympathetic activity

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient with somatic symptom disorder (confirmed by psychiatrists)
Exclusion Criteria:
  • The age is younger than 20 or older than 70 years

  • Having psychotic symptoms or cognitive impairment

  • Having a potentially lethal illness

  • Cannot read the questionnaires by oneself

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • National Taiwan University Hospital

Investigators

  • Principal Investigator: Wei-Lieh Huang, MD, PhD, National Taiwan University Hospital Yunlin Branch

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT05792930
Other Study ID Numbers:
  • 202209093RIND
First Posted:
Mar 31, 2023
Last Update Posted:
Mar 31, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by National Taiwan University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 31, 2023